FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137424771> ?p ?o ?g. }

• W2137424771 endingPage "738" @default.
• W2137424771 startingPage "732" @default.
• W2137424771 abstract "Clinical studies suggested that fampridine (4-aminopyridine) improves motor function in people with multiple sclerosis. This phase III study assessed efficacy and safety of oral, sustained-release fampridine in people with ambulatory deficits due to multiple sclerosis.We undertook a randomised, multicentre, double-blind, controlled phase III trial. We randomly assigned 301 patients with any type of multiple sclerosis to 14 weeks of treatment with either fampridine (10 mg twice daily; n=229) or placebo (n=72), using a computer-generated sequence stratified by centre. We used consistent improvement on timed 25-foot walk to define response, with proportion of timed walk responders in each treatment group as the primary outcome. We used the 12-item multiple sclerosis walking scale to validate the clinical significance of the response criterion. Efficacy analyses were based on a modified intention-to-treat population (n=296), which included all patients with any post-treatment efficacy data. The study is registered with ClinicalTrials.gov, number NCT00127530.The proportion of timed walk responders was higher in the fampridine group (78/224 or 35%) than in the placebo group (6/72 or 8%; p<0.0001). Improvement in walking speed in fampridine-treated timed walk responders, which was maintained throughout the treatment period, was 25.2% (95% CI 21.5% to 28.8%) and 4.7% (1.0% to 8.4%) in the placebo group. Timed walk responders showed greater improvement in 12-item multiple sclerosis walking scale scores (-6.84, 95% CI -9.65 to -4.02) than timed walk non-responders (0.05, -1.48 to 1.57; p=0.0002). Safety data were consistent with previous studies.Fampridine improved walking ability in some people with multiple sclerosis. This improvement was associated with a reduction of patients' reported ambulatory disability, and is a clinically meaningful therapeutic benefit." @default.
• W2137424771 created "2016-06-24" @default.
• W2137424771 creator A5010871382 @default.
• W2137424771 creator A5015098713 @default.
• W2137424771 creator A5015907065 @default.
• W2137424771 creator A5016495852 @default.
• W2137424771 creator A5017405490 @default.
• W2137424771 creator A5029171966 @default.
• W2137424771 creator A5047614045 @default.
• W2137424771 creator A5085716689 @default.
• W2137424771 date "2009-02-01" @default.
• W2137424771 modified "2023-10-01" @default.
• W2137424771 title "Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial" @default.
• W2137424771 cites W1585339973 @default.
• W2137424771 cites W1964608133 @default.
• W2137424771 cites W1967609354 @default.
• W2137424771 cites W1969198078 @default.
• W2137424771 cites W1987499148 @default.
• W2137424771 cites W1998449879 @default.
• W2137424771 cites W2007757525 @default.
• W2137424771 cites W2008849873 @default.
• W2137424771 cites W2014912839 @default.
• W2137424771 cites W2025504409 @default.
• W2137424771 cites W2028664517 @default.
• W2137424771 cites W2040917709 @default.
• W2137424771 cites W2041692743 @default.
• W2137424771 cites W2048960037 @default.
• W2137424771 cites W2050442028 @default.
• W2137424771 cites W2050824693 @default.
• W2137424771 cites W2055127611 @default.
• W2137424771 cites W2086116245 @default.
• W2137424771 cites W2092932765 @default.
• W2137424771 cites W2094518494 @default.
• W2137424771 cites W2105490558 @default.
• W2137424771 cites W2108487302 @default.
• W2137424771 cites W2112165124 @default.
• W2137424771 cites W2119629949 @default.
• W2137424771 cites W2143567192 @default.
• W2137424771 cites W2168089704 @default.
• W2137424771 doi "https://doi.org/10.1016/s0140-6736(09)60442-6" @default.
• W2137424771 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19249634" @default.
• W2137424771 hasPublicationYear "2009" @default.
• W2137424771 type Work @default.
• W2137424771 sameAs 2137424771 @default.
• W2137424771 citedByCount "471" @default.
• W2137424771 countsByYear W21374247712012 @default.
• W2137424771 countsByYear W21374247712013 @default.
• W2137424771 countsByYear W21374247712014 @default.
• W2137424771 countsByYear W21374247712015 @default.
• W2137424771 countsByYear W21374247712016 @default.
• W2137424771 countsByYear W21374247712017 @default.
• W2137424771 countsByYear W21374247712018 @default.
• W2137424771 countsByYear W21374247712019 @default.
• W2137424771 countsByYear W21374247712020 @default.
• W2137424771 countsByYear W21374247712021 @default.
• W2137424771 countsByYear W21374247712022 @default.
• W2137424771 countsByYear W21374247712023 @default.
• W2137424771 crossrefType "journal-article" @default.
• W2137424771 hasAuthorship W2137424771A5010871382 @default.
• W2137424771 hasAuthorship W2137424771A5015098713 @default.
• W2137424771 hasAuthorship W2137424771A5015907065 @default.
• W2137424771 hasAuthorship W2137424771A5016495852 @default.
• W2137424771 hasAuthorship W2137424771A5017405490 @default.
• W2137424771 hasAuthorship W2137424771A5029171966 @default.
• W2137424771 hasAuthorship W2137424771A5047614045 @default.
• W2137424771 hasAuthorship W2137424771A5085716689 @default.
• W2137424771 hasConcept C118552586 @default.
• W2137424771 hasConcept C126322002 @default.
• W2137424771 hasConcept C142724271 @default.
• W2137424771 hasConcept C168563851 @default.
• W2137424771 hasConcept C1862650 @default.
• W2137424771 hasConcept C204787440 @default.
• W2137424771 hasConcept C27081682 @default.
• W2137424771 hasConcept C2780640218 @default.
• W2137424771 hasConcept C2780892749 @default.
• W2137424771 hasConcept C2908647359 @default.
• W2137424771 hasConcept C35785553 @default.
• W2137424771 hasConcept C535046627 @default.
• W2137424771 hasConcept C70770792 @default.
• W2137424771 hasConcept C71924100 @default.
• W2137424771 hasConcept C99454951 @default.
• W2137424771 hasConcept C99508421 @default.
• W2137424771 hasConceptScore W2137424771C118552586 @default.
• W2137424771 hasConceptScore W2137424771C126322002 @default.
• W2137424771 hasConceptScore W2137424771C142724271 @default.
• W2137424771 hasConceptScore W2137424771C168563851 @default.
• W2137424771 hasConceptScore W2137424771C1862650 @default.
• W2137424771 hasConceptScore W2137424771C204787440 @default.
• W2137424771 hasConceptScore W2137424771C27081682 @default.
• W2137424771 hasConceptScore W2137424771C2780640218 @default.
• W2137424771 hasConceptScore W2137424771C2780892749 @default.
• W2137424771 hasConceptScore W2137424771C2908647359 @default.
• W2137424771 hasConceptScore W2137424771C35785553 @default.
• W2137424771 hasConceptScore W2137424771C535046627 @default.
• W2137424771 hasConceptScore W2137424771C70770792 @default.
• W2137424771 hasConceptScore W2137424771C71924100 @default.
• W2137424771 hasConceptScore W2137424771C99454951 @default.
• W2137424771 hasConceptScore W2137424771C99508421 @default.

• next